


MEN 2019

16TH INTERNATIONAL WORKSHOP
on Multiple Endocrine Neoplasia
A Focus on New Concepts and Treatment of Malignant Manifestations

**March 27-29, 2019
Houston, Texas USA**


The University of Texas
MD Anderson Cancer Center
Dan L. Duncan Building (CPB)
Floor 8, Rooms 1-8
1155 Pressler Street
Houston, Texas



THE UNIVERSITY OF TEXAS
**MD Anderson
Cancer Center**

Making Cancer History®

**FINAL
PROGRAM**



Tuesday, March 26

A Celebration of the 50th Anniversary of Screening for Hereditary Medullary Thyroid Cancer

Wednesday, March 27

7:00 am	Registration and Continental Breakfast
8:00	Welcome and Opening Remarks Elizabeth Grubbs, MD
8:05	Welcome Peter Pisters, MD President, The University of Texas MD Anderson Cancer Center
8:10	History of World MEN Conference Robert Gagel, MD
8:15	Presentation of Lifetime Achievement Award Raiesh V. Thakker, MD, SCD

Pancreatic Neuroendocrine Tumors

Moderator: Jeffrey E. Lee, MD

8:30 State of the Science with Pancreatic Neuroendocrine Tumors
Daniel Halperin, MD

8:50 Emerging Therapies and Epigenetics
Kate Lines, PhD

9:10 **Menin and Telomeres in Pancreatic Neuroendocrine Tumors**
Christopher M. Heaphy, PhD

9:30 Observational Studies of Tumor Growth
Samira Sadowski, MD

9:50 Perioperative Clinical Trials
Matthew HG Katz, MD

10:10 **Poster Preview Presentations**
Genetic Landscape of a Large Series of Sporadic Medullary Thyroid Carcinomas
Deep Sequencing
Raffaele Ciampi, PhD

Diagnosing Non-Functional Pancreatic NETs in MEN1 – The Evidence Base

ONC201 Inhibits Tumor Growth and RET Signaling Through Induction of ATF4-mediated Endoplasmic-Reticulum Stress

10:25	Break/Poster Viewing
11:00	Keynote Panel: Common Failures in Rare Diseases (optional, non-CME) Moderator: Steven Sherman, MD
	Panelists: Anne Borgman, MD Giulio Draetta, MD, PhD George A. Fisher, Jr. MD, PhD Camilo Jimenez, MD Dwight Vicks III, MBA James C. Yao, MD
12:30 pm	Lunch (provided)
	Medullary Thyroid Cancer
	Moderator: Friedhelm Raue, MD
1:15	Emerging Therapies in Medullary Thyroid Cancer
	1:15 RET Inhibitor LOXO-292 Lori J. Wirth, MD
	1:30 RET Inhibitor BLU-667 Mimi I. Hu, MD
	1:45 Future Trial Development for Medullary Thyroid Cancer Vivek Subbiah, MD
2:00	Transcriptional Targeting of OncoGene Addiction in Medullary Thyroid Cancer
	Matthew D. Ringel, MD
2:20	Lesson Learned from TCGA and Other Large Scale Genomics Programs
	Kenna Shaw, PhD
2:45	Break/Poster Viewing
3:00- 5:00	Disease Site Working Groups <ul style="list-style-type: none"> • Medullary Thyroid Cancer • Parathyroid Cancer • Pancreatic Neuroendocrine Tumor • Metastatic Pheochromocytoma and Paraganglioma
5:00 pm	Adjourn

Thursday, March 28

7:00 am	Registration and Continental Breakfast
7:30	Hereditary Gastrointestinal Neuroendocrine Tumors (optional, non-CME) <i>Sponsored by Lexicon Pharmaceuticals, Inc.</i> Arvind Dasari, MD and Boris Naraev, MD, PhD
8:00	Welcome and Opening Remarks
Metastatic Pheochromocytoma and Paraganglioma Moderator: Frederic Castinetti, MD, PhD	
8:10	State of the Science with Malignant Pheochromocytoma and Paraganglioma Roderick Clifton-Bligh, BSC (med), MBBS (hons), FRACP, PhD, FFSc (RCPA)
8:30	Radiopharmaceuticals, Tyrosine Kinase Inhibitors and Immunotherapy for Patients with Malignant Pheochromocytoma and Paraganglioma Camilo Jimenez, MD
8:50	Pseudohypoxia as a Therapeutic Target: Lessons from Clusters One and Two Patricia L. Dahia, MD, PhD
9:10	Epigenetic Characteristics of Paraganglioma Syndrome Type 4 Mercedes Robledo, PhD
9:30	Enabling Replicative Immortality in Pheochromocytoma and Paraganglioma Anne-Paule Gimenez-Roqueplo, MD, PhD
9:50	Break/Poster Viewing
<hr/>	
10:00	Keynote Lecture Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities and Prospects for Cures James Allison, PhD
11:00	Poster Preview Presentations
	Cyclin D1-Driven Parathyroid Neoplasia is CDK4/6 Dependent in Transgenic Mice Jessica Costa-Guda, DMD, PhD
	UMD---MEN1 Database: An Overview of the 370 MEN1 Variants Present in 1,676 Patients from the French Population Pauline Romanet, MD, PhD
	Tissue-Specific Tumorigenesis in Multiple Endocrine Neoplasia Type I Juliet C. Gardiner, MS
11:15	Break/Poster Viewing
11:45	Lunch (provided)

Parathyroid Cancer**Moderator: Ana Hoff, MD**

12:15 pm	Presentation of FIRMO Parathyroid Medal Maria-Luisa Brandi, MD, PhD
12:20	Genetic Syndromes of Primary Hyperparathyroidism and Parathyroid Cancer Maria-Luisa Brandi, MD, PhD
12:40	Genetic and Molecular Alterations in Parathyroid Cancer Andrew Arnold, MD
1:00	In Vivo Roles of CDC73: Insights From Mutant Mouse Models Rajesh V. Thakker, MD, SCD
1:20	The Role of Local Therapies in Parathyroid Cancer: Surgery and Radiotherapy Nancy Perrier, MD
1:40	Targeted Therapies and Trials in Parathyroid Cancer Naifa Busaidy, MD
2:00	Break/Poster Viewing
2:20- 4:20	Disease Site Working Groups <ul style="list-style-type: none">• Medullary Thyroid Cancer• Parathyroid Cancer• Pancreatic Neuroendocrine Tumor• Metastatic Pheochromocytoma and Paraganglioma
4:30	Adjourn
6:30 pm	Dinner at Space Center Houston

Friday, March 29

7:00 am	Registration and Continental Breakfast
8:00	Welcome and Opening Remarks
	Pituitary/Adrenocortical Tumors and Von Hippel-Lindau Disease
	Moderator: Steven Wagstaff, MD
8:10	Aggressive Pituitary Tumors: An Update on Pathologic Features and Genomics Gérald Raverot, MD, PhD
8:30	What is New in Familial Isolated Pituitary Adenoma? Albert Beckers, MD, PhD
8:50	X-LAG: An Update Constantine Stratakis, MD, DMSci
9:10	The Genetics of and New Molecular Insights into Adrenocortical Carcinoma Tobias Elise, MD

9:30 **Benign Adrenocortical Tumors**
 Jérôme Bertherat, MD, PhD

9:50 **VHL as a Paradigm for the Simultaneous Treatment of Multiple Hereditary Tumors**
 Eric Jonasch, MD

10:10 **VHL and Pancreatic NETs: An Update**
 Electron Kebebew, MD

10:30 Break

10:45 **Summary of Working Groups and AMEND USA Poster Award Presentation**

12:00 pm Adjourn